Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer.

By Mark R. Green, G. Manikhas, S. Orlov, B. Afanasyev, A. Makhson, P. Bhar, M. Hawkins. Annals of Oncology, 2006

614 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/670e5b72df22e11688860f0a7e123a3c0b4424d7

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. D. Newman
2. G. Cragg
3. Colin W. Pouton
4. D. McClements
5. Jiajia Rao

Citations in the corpus

• Strategies to Address Low Drug Solubility in Discovery and Development (2013, background): “Abraxane (Celgene, Summit, NJ) is another Cremophor-free formulation for paclitaxel where the drug is bound to albumin particles (Green et al., 2006).”
• NATURAL PRODUCTS: A CONTINUING SOURCE OF NOVEL DRUG LEADS (2013, background): “The clinically-approved new albumin-bound formulation of paclitaxel known as Abraxane® offers some significant advantages compared with the original Cremophor formulation [29], and a nanoparticle formulation in cross-linked polymers with paclitaxel contained in the microspheres was approved in India”